

---

# Canadian Life Sciences Trade Mission

New York & New Jersey

May 11 – 14, 2026

---

## Delegation Directory



Canada 

## About the Ontario Trade & Investment Office in New York

The Government of Ontario, Canada operates a network of International Trade and Investment Offices, located in Canadian diplomatic Missions around the world.

Working closely with Canadian federal, provincial and municipal partners, these offices raise Ontario's profile and build commercial relations in key global markets. They promote exports from Ontario, attract new companies, offices and facilities to Ontario.

**The New York Office** is dedicated to advancing the economic objectives of Ontario in the Northeastern United States. This territory spans across the states of New York, New Jersey, Pennsylvania, Massachusetts, Connecticut, Delaware, Maine, New Hampshire, Vermont and Rhode Island.

### **Charley Ford**

Senior Commercial Officer

[charley.ford@international.gc.ca](mailto:charley.ford@international.gc.ca)

---

## About the Trade Commissioner Service in New York

The Canadian Trade Commissioner Service (TCS) is the federal government's network of trade professionals working in offices across Canada and in over 160 cities worldwide. TCS trade commissioners help Canadian companies grow their international business by providing market insights, expansion advisory services and qualified contacts in market.

**The NYC Trade Commissioner team** works within a five-state remit on the US east coast: Pennsylvania, New York, New Jersey, Connecticut and Delaware. The team helps Canadian firms connect with buyers and investors and works with US firms who are ready to explore Canadian expansion.

### **Max Lelu**

Trade Commissioner

[max.lelu@international.gc.ca](mailto:max.lelu@international.gc.ca)

# Canada's Life Sciences Ecosystem

Canada is home to a thriving and globally competitive life sciences ecosystem, anchored by world-class research institutions, a deep talent pipeline, and a business environment purpose-built for innovation.


## Why US companies partner with Canada:

- Competitive R&D tax incentives, including the Scientific Research & Experimental Development (SR&ED) program, one of the most generous in the G7.
- A deep and diverse talent pipeline, with over 50 research-intensive universities producing highly skilled graduates in STEM, health sciences, and AI.
- Universal healthcare data sets that support population-level research, clinical trials, and real-world evidence generation.
- Proximity to the US market, with same-timezone operations and integrated supply chains across the border.
- A cost-competitive environment, with operating costs 20–30% lower than comparable US cities for R&D and manufacturing.

**Ontario**, Canada's largest province, is the heart of the country's life sciences sector, with over 1,900 life sciences firms, 5 of the top 10 research hospitals in Canada, and established clusters in Toronto, Ottawa, Kitchener-Waterloo, and Hamilton.

## The Delegation

The following Ontario-based life sciences companies are participating in the Canadian Life Sciences Trade Mission to New York and New Jersey, May 11–14, 2026.



## FemmeBright Health

# FemmeBright HEALTH ———

**Delegate:** Lisa Lechner

**Title:** Founder & CEO

**Email:** [lisa.lechner@femmebright.com](mailto:lisa.lechner@femmebright.com)

**Website:** <https://femmebright.com>

FemmeBright Health is a digital health company improving the lives of women impacted by chronic and life-changing health conditions, leading with autoimmune health. Their virtual clinic and health platform supports every woman's health journey with personalized, female-oriented content, resources, and services, including on-demand access to healthcare providers and relevant practitioners.

---

## HDAX Therapeutics



**Delegate:** Nabanita Nawar, PhD

**Title:** CEO & Cofounder

**Email:** [nabanita@hdaxtx.com](mailto:nabanita@hdaxtx.com)

**Website:** <https://hdaxtx.com>

HDAX Therapeutics is a biotechnology company pioneering a novel approach to targeting HDAC6 for the discovery and development of breakthrough therapeutics for high unmet medical needs in renal, cardiometabolic, and select neurological diseases. Their innovative 2-site binding mechanism has the potential to deliver best-in-class HDAC6-targeting therapeutics, addressing critical drug-design challenges that have limited first-generation compounds.

## Eurofins CDMO Alphora



**Delegate:** Brandon Nam

**Title:** Senior Business Development Executive

**Email:** brandon.nam@bpt.eurofinsca.com

**Website:** <https://www.eurofins.com/biopharma-services/cdmoeurofins-alphora/>

Located in Mississauga, Ontario, Eurofins CDMO Alphora delivers comprehensive solutions for small molecule & biologic drug substance and drug product — all under one roof. Our small molecule capabilities include the development and manufacture of API's and HPAPI's, oral drug products and API solid-state R&D. Our biologics capabilities include the development and manufacture of mAbs, proteins and ADC's, and Sterile Fill (2026). With over 250 skilled professionals, a facility inspected by the FDA, Health Canada, and Japan's PMDA, we've been a trusted partner since 2003. Our integrated services span pre-clinical to commercial stages — accelerating timelines and ensuring quality at every step.

---

## Healthyher.Life



**Delegate:** Rina Carlini, PhD

**Title:** Founder & CEO

**Email:** rina@healthyher.life

**Website:** <https://www.healthyher.life>

Healthyher.Life™ is an AI-guided women's health care platform that helps clinics, pharmacies, and workplaces to offer women and patients personalized access to trusted health and wellness education, physician appointments, and 24/7 virtual patient support, navigated by Hailey®, Your AI Health Concierge®. We bridge the gaps of patient education, navigation and virtual support in women's health.

## Spectrum Medical Diagnostics



**Delegate:** Sharmila Sriram

**Title:** Founder & CEO

**Email:** sharmin@spectrummdx.com

**Website:** <https://spectrummdx.com>

Sharmila Sriram is the Founder & CEO of Spectrum Medical Diagnostics and ResultsPlus, with over 30 years of experience in the medical device industry. She leads an award-winning, women-led healthcare company advancing point-of-care diagnostics, environmental health solutions, and an AI-driven platform that integrates biological and environmental data to enable more preventative, data-driven healthcare. Her work focuses on improving early detection, expanding access to care, and supporting more intelligent, globally scalable healthcare systems.

---

## OmniaBio



**Delegate:** Brian Walsh

**Title:** SVP, Global Business Development

**Email:** brian.walsh@omnia.bio

**Website:** <https://omnia.bio>

OmniaBio Inc. provides specialized, focused, cGMP-compliant CDMO services for cell and gene therapy (CGT) developers from pre-clinical through to commercial stage. As a CCRM subsidiary, OmniaBio is building on an established reputation in CGT manufacturing from a team and legacy that has been built over a decade. With leadership in induced Pluripotent Stem Cells, immunotherapy and Lentiviral Vectors, OmniaBio provides a continuum of advanced process and analytical development, and manufacturing capabilities. Located in Hamilton, Ontario, Canada, OmniaBio's site is a one-hour drive from the U.S. border.

## MEMOTEXT



MEMOTEXT

**Delegate:** Amos Adler

**Title:** CEO

**Email:** amos@memotext.com

**Website:** <https://memotext.com>

MEMOTEXT® is a clinical-grade platform and marketplace for digital patient engagement. Trusted since 2012 and backed by 21 peer-reviewed publications across mental health, chronic disease, and specialty care. Specializing in Just-In-Time Adaptive Interventions (JITAI), MEMOTEXT delivers personalized, omnichannel support driven by behavioral data, clinical milestones, and real-world health inputs, with validated outcomes including a 31.4% increase in medication adherence, 50% reduction in early treatment discontinuation, and 91% patient retention. As the field has evolved, so has MEMOTEXT: mtxt.ai extends that foundation into a governed, AI-assisted environment where clinicians and researchers can move from intervention concept to structured, ethics- and HIPAA-compliant feasibility documentation and prototyping, closing the translational gap between clinical intent and deployable, validatable digital health solutions.

---

## Intrepid Labs



**Delegate:** Michael Craig

**Title:** Head of Machine Learning

**Email:** michael@intrepidlabs.ai

**Website:** <https://www.intrepidlabs.tech>

Intrepid Labs uses AI, robotics, and automation to accelerate drug formulation and development. Their proprietary Valiant platform offers a closed-loop system that compresses drug design timelines from months to days, enabling pharmaceutical companies to bring therapies to market faster and more efficiently.

## Rocket Doctor



**Delegate:** William Cherniak

**Title:** Founder & CEO

**Email:** [bill@rocketdoctor.io](mailto:bill@rocketdoctor.io)

**Website:** <https://rocketdoctor.io>

Rocket Doctor is a technology-driven digital health platform and marketplace that empowers healthcare providers to break down barriers preventing patients from accessing high-quality, comprehensive, and affordable care, especially those on Medicaid and in rural and remote communities.

---

## Covar Pharmaceuticals



**Delegate:** Jonathan Chow

**Title:** Senior Manager, Business Development

**Email:** [jonathan.chow@covarpharma.com](mailto:jonathan.chow@covarpharma.com)

**Website:** <https://www.covarpharma.com>

Covar Pharmaceuticals specializes in contract development services for small-molecule NCEs, 505(b)(2) products, and complex generics. Our capabilities include preformulation, formulation development, clinical supply manufacturing, regulatory strategy, and FDA/Health Canada submissions across a broad range of dosage forms, including solid orals, topicals, liquid formulations, and inhalation & nasal products. Covar's Mississauga, Ontario facility is Health Canada-inspected and is equipped to support the development of highly potent active ingredients and controlled substances.

## NuraLogix



**Delegate:** Vince Traylor

**Title:** Director, Sales and Partnerships — US Market

**Email:** [vincetraylor@nuralogix.ai](mailto:vincetraylor@nuralogix.ai)

**Website:** <https://www.nuralogix.ai>

NuraLogix is the global leader of contactless health measurement. Its latest innovation, an AI-powered Longevity Mirror™, transforms a simple 30-second mirror moment into a powerful check-in on long-term wellness — delivering over 30 insights from a selfie video. At the core is LIX™ (Longevity Index), a proprietary score that helps individuals understand their health trajectory and future risk, turning everyday interactions into actionable, forward-looking health insights.

---

## Cancard Inc.



**Delegate:** Deepak Sharma (CEO) & Avinash Jayaswal (Chief Medical Officer)

**Title:** CEO & Chief Medical Officer

**Email:** [dsharma@cancard.com](mailto:dsharma@cancard.com) | [drajayaswal@cancard.com](mailto:drajayaswal@cancard.com)

**Website:** <https://cancard.com>

Cancard is a Canadian technology company operating since 1989, with offices in Toronto, New York, and New Delhi. Cancard offers a unique combination of advanced hardware portfolio of hospital equipment integrated with IOT, Sensors, Edge AI along with cutting-edge AI-powered digital health solutions. This capability allows us to deliver hardware and software solutions that are designed, connected, and optimized to solve critical unmet needs for caregivers, physicians, nurses, and patients. Our latest innovation is a next-generation AI population health solution designed to simplify and streamline chronic disease management with integrated vital sensors, real-time patient monitoring, advanced care-coordination planning, AI risk stratification to reduce readmissions, improve patient outcomes and lower costs. Cancard is actively looking to expand our presence in global markets, including US, India and ME, and are looking for partners, investors, and advisors to join us in this journey.

## Mesh AI



**Delegate:** Shahram Yousefi

**Title:** CEO & Co-founder

**Email:** [president@meshai.io](mailto:president@meshai.io)

**Website:** <https://meshai.io>

Mesh AI is a Healthcare Workforce Intelligence Platform that provides hospital leadership with a single source of truth for physician scheduling. By unifying scheduling rules, workflows, and data across departments, Mesh AI enables real-time visibility into coverage, identifies gaps before they become risks, and ensures fair, compliant, and efficient workforce allocation. The result: reduced operational friction, lower reliance on last-minute fixes, improved physician wellness, and greater confidence in delivering care.

---

## YYZ Pharmatech Inc.



**P H A R M A T E C H I N C .**

**Delegate:** Michael Badeau

**Title:** President & CEO

**Email:** [michael@badeau.ca](mailto:michael@badeau.ca)

**Website:** <https://yyzpharmatech.com>

YYZ Pharmatech Inc. (“YYZ”) reveals novel, proximal, functional co-receptor drug targets from the surface of ligand-activated live human cells – to meaningfully enable first-in-class biologic and small molecule treatments for patients.

BCG estimates that 60% of pharma’s total projected global pipeline value is now new modalities (i.e. mAbs, ADCs, CAR-T), while only 10-15% of the surfaceome is considered well-characterized – target innovation (not modality innovation) is the principal bottleneck in next-gen drug development, and YYZ’s technologies bridge this critical gap.

YYZ is a member of JLABS, BioLabs and many of Canada’s leading accelerators and consortia. Our scientific foundation is built on the pioneering research of Dr. John G. Marshall, over 150 publications and extensive collaboration with leading international institutions.

## 49Care



**Delegate:** Marion Ulmann

**Title:** Director

**Email:** marion@49care.com

**Website:** <https://www.49care.com>

49Care is a Canadian pharmaceutical company transforming women's health by delivering the care and technologies women deserve.

We are committed to expanding access to high-quality health solutions while ensuring innovation, accessibility, and safety for every patient.